

Contents

Preface *xiii*

A Personal Foreword *xv*

Part I Introduction 1

1	Polypharmacology in Drug Discovery	3
	<i>Oscar Méndez-Lucio, J. Jesús Naveja, Hugo Vite-Caritino, Fernando D. Prieto-Martínez, and José L. Medina-Franco</i>	
1.1	Polypharmacology	3
1.2	Multitarget versus Target-Specific Drugs	5
1.2.1	“Master Key Compounds”	5
1.2.2	Safety Panels	8
1.3	Polypharmacology and Related Concepts in Drug Discovery	11
1.3.1	Drug Repurposing	11
1.3.2	Combination of Drugs	12
1.3.3	<i>In Vivo</i> Testing	12
1.4	Polypharmacology (and Polypharmacy): Case Studies	13
1.4.1	Polypharmacology in Epigenetics	13
1.4.2	Charting the Epigenetic Relevant Chemical Space	14
1.4.3	Polypharmacy for the Treatment of HIV Infections	15
1.5	Computational Strategies to Explore Polypharmacology	15
1.5.1	Chemogenomics: Intersection of Chemical and Biological Spaces	16
1.5.2	Structure–Multiple Activity Relationships	17
1.5.3	Proteochemometric Modeling	19
1.5.4	Target Fishing	19
1.5.5	Data Mining of Side Effects and Interactions for Drug Repurposing	20
1.5.6	Systems Pharmacology	21
1.5.7	Polypharmacology Fingerprints	21
1.6	Summary Conclusions	21
	Acknowledgments	22
	References	22

Part II Selectivity of Marketed Drugs 31

- 2 Kinase Inhibitors 33**
Peng Wu, Michael Givskov, and Thomas E. Nielsen
- 2.1 Overview 33
- 2.2 Kinase Profiling 38
- 2.3 Definition and Quantification of Selectivity Levels 40
- 2.4 Selectivity of Approved Kinase Inhibitors 43
- 2.4.1 Non-covalent Type I and Type II SMKIs 45
- 2.4.2 Allosteric SMKIs 47
- 2.4.3 Lipid Kinase Inhibitor 48
- 2.4.4 Covalent Inhibitors 48
- 2.5 Conclusion and Perspective 48
- Acknowledgment 49
- References 49
- 3 Repositioning of Drug – New Indications for Marketed Drugs 55**
Ren Kong and Stephen T. Wong
- 3.1 Introduction 55
- 3.2 New Uses from Adverse Effects 57
- 3.2.1 Dapoxetine for Premature Ejaculation 57
- 3.2.2 Sildenafil for Erectile Dysfunction 58
- 3.3 New Uses Based on Known Mechanism of Action 58
- 3.3.1 Duloxetine for Stress Urinary Incontinence (SUI) 58
- 3.3.2 Thalidomide for Erythema Nodosum Leprosum (ENL) and Multiple Myeloma 59
- 3.4 New Uses from Genome, Network, and Signal Pathway Analysis 59
- 3.4.1 Identification of Sunitinib and Dasatinib for Breast Cancer Brain Metastasis 59
- 3.5 New Uses Based on New Target Identification (Off-Target Effects) 62
- 3.5.1 Antidepressant Drug, Amoxapine, for Alleviating Cancer Drug Toxicity of Irinotecan 62
- 3.6 Computational and Systematic Drug Repositioning 64
- 3.6.1 Methods Based on Knowledge of Side Effects 64
- 3.6.2 Methods Based on Transcriptomics Data (Transcriptional Profile) 65
- 3.6.3 Methods Based on Genome-Wide Association Study (GWAS) 66
- 3.6.4 Methods Based on Network and Pathways Analysis 66
- 3.6.5 Methods Based on Off-Target Effects 67
- 3.7 Perspective 68
- Acknowledgment 73
- References 73
- 4 Discovery Technologies for Drug Repurposing 79**
Naiem T. Issa, Stephen W. Byers, and Sivanesan Dakshanamurthy
- 4.1 Introduction 79
- 4.2 Biological Drug Screening Methods 79

4.2.1	Phenotypic Screening	79
4.2.1.1	Animal-Based Screening	80
4.2.1.2	Cell-Based Screening	80
4.2.2	Target-Based Screening	81
4.3	<i>In silico</i> Tools for Drug Repurposing	82
4.3.1	Docking	82
4.3.2	Cheminformatics	83
4.3.3	Protein Binding Site	84
4.3.4	Combining Drug-Centric with Protein-Centric Approaches	86
4.3.5	Network Pharmacology	86
4.3.6	Mining of Big Data	88
4.4	Conclusion	89
	References	90

Part III Unselective Drugs in Drug Discovery 101

5	Personalized Medicine	103
	<i>Christian Noe and Volker Baumann</i>	
5.1	Roots of Personalized Medicine	103
5.2	The Return of the Active Pharmaceutical Ingredients (APIs)	104
5.3	Systems Pharmacology	105
5.4	The Patient in the Focus of Research	107
5.5	Personalized Therapy	107
5.6	Gene Therapy	108
5.7	Regenerative Medicine	110
5.8	Individualized Medicines	110
5.9	Stratified Medicines	112
5.10	Drug Selectivity	113
5.11	Smart Innovation	114
5.12	Electronic Health	115
5.13	Doctor and Patient	115
5.14	The Competent Patient	116
5.15	Conclusion	117
	References	117
6	Drug Discovery Strategies for the Generation of Multitarget Ligands against Neglected Tropical Diseases	135
	<i>Annachiara Gandini, Federica Prati, Elisa Uliassi, and Maria L. Bolognesi</i>	
6.1	Introduction	135
6.2	Drug Discovery for NTDs: The Past, the Present, and the Future	136
6.3	Search for New Anti-Trypanosomatid MTDL Hits: A Phenotypic Approach	138
6.4	Search for New Anti-Trypanosomatid MTDL Hits: A Target-Based Approach	141
6.5	Search for New Anti-Trypanosomatid MTDL Hits: A Drug Targeting Approach	146

6.6	Search for New Anti-Trypanosomatid MTDL Hits: A Combined Target/Targeting Approach	149
6.7	Conclusions	151
	References	152
7	Designing Approaches to Multitarget Drugs	161
	<i>Luca Costantino and Daniela Barlocco</i>	
7.1	Introduction	161
7.2	Target-Based Approaches for Multitarget Drug Design	163
7.2.1	Designing Approaches for Structurally Related Targets	163
7.2.1.1	Fragment-Based Approach	163
7.2.2	Designing Approaches for Structurally Unrelated Targets	166
7.2.2.1	Crystallography/SAR	166
7.2.2.2	Molecular Docking/Pharmacophore Matching	167
7.3	Ligand-Based Approaches for Multitarget Drug Design	170
7.3.1	Designing Approaches for Structurally Related Targets	170
7.3.1.1	Fragment-Based Approach	170
7.3.1.2	Machine Learning	171
7.3.1.3	SAR around a Lead	173
7.3.1.4	Pharmacophore-Based Approach	176
7.3.2	Designing-In Approaches for Structurally Unrelated Targets	180
7.3.2.1	Fragment-Based Approach	180
7.3.2.2	Pharmacophore-Based Approach	180
7.3.2.3	SAR around a Lead	181
7.3.2.4	Mining Literature Data	183
7.4	Designing Approaches Based on Phenotypic Assays	186
7.5	Conclusions	189
	References	191
8	The Linker Approach: Drug Conjugates	207
	<i>Daniel Merk and Manfred Schubert-Zsilavecz</i>	
8.1	Introduction	207
8.1.1	Targeted Delivery	209
8.2	Drug Conjugates	209
8.2.1	Small Molecule Drug Conjugates	209
8.2.1.1	Chances and Challenges	209
8.2.1.2	Examples	210
8.2.2	Antibody–Drug Conjugates/Protein–Drug Conjugates	217
8.2.2.1	Chances and Challenges	218
8.2.2.2	Examples	219
8.2.3	Polymer–Drug Conjugates	223
8.2.3.1	Chances and Challenges	223
8.2.3.2	Examples	226
8.3	Linker Chemistry	229
8.3.1	Demands on a Linker or How to Link Drugs	229
8.3.2	Linker Types	231
8.4	Conclusion and Future Perspective	233
	References	236

9	Merged Multiple Ligands	247
	<i>Hongming Chen, Udo Bauer, and Ola Engkvist</i>	
9.1	Introduction	247
9.2	Computational Methods Utilized in Designing MMLs	248
9.2.1	Bioactivity Data Sources	248
9.2.2	Utilizing Known Polypharmacology to Identify MMLs	248
9.2.3	Applying QSAR Models to Identifying and Optimizing MMLs	249
9.2.4	MMLs Developed Based on Fragments	250
9.2.5	Utilizing Protein Crystal Structures in Identifying MMLs	250
9.3	Examples of Medicinal Chemistry Efforts of Designing MMLs in Drug Discovery Projects	251
9.3.1	MMLs in Oncology	251
9.3.2	MML Targeting for Neurodegenerative Disease	255
9.3.2.1	MMLs for the Treatment of Alzheimer's Disease	256
9.3.2.2	MML for the Treatment of Parkinson's Disease	257
9.3.3	MML for the Treatment of Depression	261
9.3.4	MMLs for the Treatment of Cardiovascular Diseases	262
9.3.5	MML for the Treatment of Diabetes and Related Metabolic Diseases	264
9.3.6	MML for the Treatment of Inflammation and Pain	267
9.4	Conclusions and Future Outlook	269
	References	269
10	Pharmacophore Generation for Multiple Ligands	275
	<i>Norbert Handler</i>	
10.1	Introduction	275
10.2	Ligand-Based Pharmacophore Modeling	276
10.3	Structure-Based Pharmacophore Modeling	278
10.4	Pharmacophore-Based Virtual Screening	279
10.5	Pharmacophore-Based <i>De Novo</i> Design	280
10.6	Limitations for Pharmacophore Modeling	282
10.7	Practical Strategy for Pharmacophore-Based Discovery of Multiple Ligands	283
10.8	Linked Fluoroquinolone–Flavonoid Hybrids as Potent Antibiotics against Drug-Resistant Microorganisms	285
10.9	<i>N</i> -Phenylquinazolin-4-Amine Hybrids as Dual Inhibitors of VEGFR-2 and HDAC	286
10.10	Dual Inhibitors of Phospholipase A2 and Human Leukotriene A4 Hydrolase as Anti-Inflammatory Drugs	287
10.11	Dual Antagonists of the Bradykinin B ₁ and B ₂ Receptors Based on a Postulated Common Pharmacophore from Existing Non-Peptide Antagonists	290
10.12	Dual-Acting Peptidomimetics with Opioid Agonist–Neurokinin-1 Antagonist Effect	292
10.13	Novel Dual-Acting Compounds Targeting the Adenosine A _{2A} Receptor and Adenosine Transporter for Neuroprotection	292
10.14	Aminobenzimidazoles as Dual-Acting Butyrylcholinesterase Inhibitors and hCB ₂ R Ligands to Combat Neurodegenerative Disorders	295

- 10.15 Dual Acetylcholinesterase Inhibitors–Histamine H3 Receptor Antagonists for Treating Alzheimer’s Disease 297
- 10.16 Identification of Potential Dual Agonists of FXR and TGR5 Using E-Pharmacophore-Based Virtual Screening 299
- 10.17 Arylboronic Acids as Dual-Acting FAAH and TRPV1 Ligands 301
- 10.18 Dual Type II Inhibitors of TGF β -Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase 2 (MAP4K2) 304
- 10.19 Conclusion and Outlook 307
References 307

11 Cellular Assays 313

Ye Fang

- 11.1 Introduction 313
- 11.2 Cell-Based Molecular Assays 314
 - 11.2.1 Ligand Binding Assays 314
 - 11.2.2 Chemoproteomic-Based Assays 315
 - 11.2.3 Signaling Assays 317
 - 11.2.4 Automated Patch Clamping 318
 - 11.2.5 Protein–Protein Interaction Assays 319
 - 11.2.6 Protein Trafficking Assays 319
 - 11.2.7 Chemogenomic-Based Assays 320
- 11.3 Cell Phenotypic Assays 321
 - 11.3.1 Reporter Gene Assays 322
 - 11.3.2 High Content Imaging Assays 323
 - 11.3.3 Label-Free Cell Phenotypic Assays 324
- 11.4 Summary 326
- 11.5 Current and Future Perspectives 326
References 327

Part IV Therapeutic Areas for Designed Multiple Ligands 335

12 Developing Serotonergic Antidepressants Acting on More Than the Serotonin Transporter 337

Gerard J. Marek

- 12.1 5-HT Transporter-Based Multiple Ligands for Depression 337
- 12.2 Beyond SSRIs: Strategies to Improve upon SSRI Antidepressant Activity 338
- 12.3 Roster of Serotonergic Targets for Drug Developed Outside of the Serotonin Transporter (SERT) 339
- 12.4 Previously Approved Antidepressants with Multiple Serotonergic Molecular Targets 340
- 12.5 Tested and Failed/Technically Difficult Dual-Acting Serotonergic Compounds 347
- 12.6 Technical Challenges to Developing New Chemical Entities with Multiple Mechanisms of Action 348

- 12.7 Clinical Experiments with SSRIs and 5-HT_{1A} Agonists/Antagonists 350
- 12.8 Clinical Experiments with SSRIs and Drugs Possessing 5-HT_{2A} Receptor Blockade 353
- 12.9 Non-SERT Serotonergic Targets Mired in Phase 2/3 355
- 12.10 Conclusions and Outlook 356
 - List of Abbreviations 357
 - References 357

- 13 Multiple Ligands Targeting the Angiotensin System for Hypertension 369**
Agustin Casimiro-Garcia
 - 13.1 Recent Advances in the Structural Basis for AT₁ Receptor Ligand Binding 370
 - 13.2 Design of Dual AT₁ and Endothelin A Receptor Antagonists 372
 - 13.3 Design of Dual AT₁ Receptor Antagonist/PPAR γ Partial Agonists 377
 - 13.4 Design of Dual AT₁ Receptor Blocker/NO-Releasing Agents 382
 - 13.5 Design of Dual AT₁ Receptor Blocker/Antioxidant Activity Agents 384
 - 13.6 Design of AT₁ Receptor Antagonists with Additional Activity in Other Pathways 387
 - 13.7 Summary 388
 - References 389

- 14 Multiple Peroxisome Proliferator-Activated Receptor-Based Ligands 397**
Dmytro Kukhtar, Miquel Mulero, Raul Beltrán-Debón, Cristina Valls, Gerard Pujadas, and Santiago Garcia-Vallve
 - 14.1 Introduction 397
 - 14.2 Dual and Pan PPAR Agonists 404
 - 14.3 Other Multiple Ligands that Act through PPARs 415
 - 14.3.1 Angiotensin II Receptor Blockers/PPAR γ Agonists 415
 - 14.3.2 COX Inhibitors/PPAR γ Agonists 421
 - 14.3.3 Protein Tyrosine Phosphatase 1B Inhibitors/PPAR Agonists 423
 - 14.3.4 11 β -Hydroxysteroid Dehydrogenase Type 1 Inhibitors/PPAR Agonists 423
 - 14.4 Conclusions 424
 - Acknowledgments 424
 - List of Abbreviations 424
 - References 424

- 15 Antibiotics 433**
Jean-Philippe Surivet and Philippe Panchaud
 - 15.1 Design of Single-Pharmacophore Molecules Acting on Multiple Targets 434
 - 15.1.1 Dual Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV 434

- 15.1.1.1 Dual Inhibitors Targeting the Binding Site of Fluoroquinolones 435
- 15.1.1.2 (Non-fluoroquinolone) Dual Inhibitors of DNA Topoisomerases 439
- 15.1.1.3 Designed Multitarget-Directed Ligands Addressing the ATP-Binding Pocket 445
- 15.1.2 Multitarget Inhibitors of Peptidoglycan Biosynthesis 451
- 15.1.3 Multitarget Inhibitors of Type II Fatty Acid Synthases 454
- 15.2 Design of Hybrid Molecules: Dual Pharmacophores Acting on Multiple Targets 456
 - 15.2.1 Cephalosporin-Based Hybrid Molecules 457
 - 15.2.2 Fluoroquinolone–Oxazolidinone Hybrid Drugs 459
 - 15.2.3 Fluoroquinolone–Aminouracil Hybrid Drugs 461
 - 15.2.4 Fluoroquinolizine–Rifamycin Hybrid Drugs 462
 - 15.2.5 Hybrid Molecules: Limitations and Perspectives 463
- 15.3 Emerging Antibacterial Drugs Allowing Multitarget-Directed Ligand Design 464
- 15.4 Conclusion 465
- References 466

16 Multiple Ligands in Neurodegenerative Diseases 477

Julien Lalut, Christophe Rochais, and Patrick Dallemane

- 16.1 Introduction 477
- 16.2 Molecular Bases of ALZHEIMER'S Disease 478
 - 16.2.1 Amyloid Plaques 478
 - 16.2.1.1 The Origin of A β Peptide Formation 478
 - 16.2.1.2 Amyloid Plaque Aggregation 480
 - 16.2.2 The Amyloid Cascade Hypothesis 480
 - 16.2.3 Neurofibrillary Tangles 481
 - 16.2.4 Oxidative Stress, Neuroinflammation, and Metal Toxicity 481
- 16.3 MTDLs Developed for the Treatment of Alzheimer's Disease 483
 - 16.3.1 MTDLs Based on Acetylcholinesterase Inhibition 483
 - 16.3.1.1 Multi-site AChE Inhibitors and Antioxidants 485
 - 16.3.1.2 Multi-site AChE Inhibitors and Metal Chelators 485
 - 16.3.1.3 Multi-site AChE and MAO Inhibitors 486
 - 16.3.2 Multi-site AChE Inhibitors and Serotonin 5-HT₄ Receptor Agonist 486
 - 16.3.2.1 Multi-site AChE and M2 Muscarinic Receptor Inhibitors 491
 - 16.3.2.2 AChE Inhibitors with a Complex Pharmacological Profile 492
 - 16.3.3 MTDLs Targeting Other Activities Relevant for the Treatment of AD 496
 - 16.3.3.1 MTDLs Modulating γ -Secretase and PPAR γ 496
 - 16.3.3.2 MTDL BACE1 Inhibitors/Metal Chelators 497
 - 16.3.3.3 MTDLs Inhibiting Muscarinic and σ 1 Receptors 498
- 16.4 Parkinson's Disease 501
- 16.5 Conclusion 502
- References 503